Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) CEO Raju Mohan sold 4,312 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $5.40, for a total transaction of $23,284.80. Following the completion of the transaction, the chief executive officer now directly owns 1,578,250 shares of the company's stock, valued at approximately $8,522,550. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Ventyx Biosciences Stock Down 1.1 %
VTYX opened at $5.18 on Thursday. Ventyx Biosciences, Inc. has a twelve month low of $1.87 and a twelve month high of $40.58. The company has a fifty day moving average of $5.33 and a 200-day moving average of $8.84. The stock has a market cap of $306.93 million, a PE ratio of -1.57 and a beta of 0.27.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.08. During the same quarter in the prior year, the business earned ($0.62) EPS. Sell-side analysts anticipate that Ventyx Biosciences, Inc. will post -2.55 EPS for the current fiscal year.
Institutional Inflows and Outflows
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Several institutional investors and hedge funds have recently bought and sold shares of VTYX. Legal & General Group Plc boosted its stake in Ventyx Biosciences by 152.3% during the second quarter. Legal & General Group Plc now owns 2,422 shares of the company's stock worth $30,000 after acquiring an additional 1,462 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Ventyx Biosciences during the fourth quarter worth $32,000. Schroder Investment Management Group bought a new position in shares of Ventyx Biosciences in the fourth quarter valued at $37,000. UBS Group AG bought a new position in shares of Ventyx Biosciences in the fourth quarter valued at $40,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Ventyx Biosciences by 1,424.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company's stock valued at $49,000 after buying an additional 18,620 shares in the last quarter. 97.88% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
VTYX has been the subject of several research reports. Lifesci Capital raised shares of Ventyx Biosciences from a "market perform" rating to an "outperform" rating in a research note on Wednesday, February 28th. Oppenheimer raised shares of Ventyx Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 price objective for the company in a research note on Tuesday, March 12th. Canaccord Genuity Group decreased their price target on shares of Ventyx Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Wednesday, March 13th. Finally, Wells Fargo & Company upgraded shares of Ventyx Biosciences from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $7.00 to $16.00 in a research report on Tuesday, March 12th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.75.
View Our Latest Analysis on VTYX
About Ventyx Biosciences
(
Get Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
